Drug Profile
m 102.4
Alternative Names: Antiviral monoclonal antibody - Profectus BioSciences; Hendra virus monoclonal antibody - Profectus BioSciences; m 102.4 - Mapp Biopharmaceutical; m102.4; m102.4 mAb; Nipah virus monoclonal antibody - Profectus BioSciencesLatest Information Update: 19 Apr 2024
Price :
$50
*
At a glance
- Originator Henry M. Jackson Foundation for the Advancement of Military Medicine; National Cancer Institute (USA); Profectus Biosciences; Uniformed Services University of the Health Sciences
- Developer Mapp Biopharmaceutical; Profectus Biosciences
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Eph family receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Henipavirus infections; Nipah virus infections
Most Recent Events
- 19 Apr 2024 m 102.4 is still in preclinical trials for Nipah virus infections in USA (IM) (Mapp Biopharmaceutical pipeline, April 2024)
- 19 Apr 2024 Preclinical trials in Henipavirus infections in USA (IM) as of April 2024 (Mapp Biopharmaceutical pipeline, April 2024)
- 28 May 2020 No recent reports of development identified for preclinical development in Nipah-virus-infections (IM) in USA